Immunomodulatory News and Research

RSS
RayBiotech's array system identifies key factors involved in dissemination of leprosy infection

RayBiotech's array system identifies key factors involved in dissemination of leprosy infection

arGEN-X advances ARGX-112 into formal preclinical development

arGEN-X advances ARGX-112 into formal preclinical development

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Miscarriage and molecular signals: an interview with Prof Brosens and Prof Quenby

Miscarriage and molecular signals: an interview with Prof Brosens and Prof Quenby

CRI, SU2C form Cancer Immunology Translational Research Dream Team

CRI, SU2C form Cancer Immunology Translational Research Dream Team

Pomalidomide safe and effective in treating multiple myeloma

Pomalidomide safe and effective in treating multiple myeloma

Study to discover exactly how intravenous immune globulin treatments work

Study to discover exactly how intravenous immune globulin treatments work

Radiotherapy protocol deviations: an interview with Dr Nitin Ohri

Radiotherapy protocol deviations: an interview with Dr Nitin Ohri

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Investigators provide overview of role of dopamine in modulating the immune system

Investigators provide overview of role of dopamine in modulating the immune system

Recovering Treg cells in pancreatic lymph nodes may restore insulin production in type I diabetics

Recovering Treg cells in pancreatic lymph nodes may restore insulin production in type I diabetics

Hydroxychloroquine fails to modify HIV in patients not taking ART

Hydroxychloroquine fails to modify HIV in patients not taking ART

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

Onyx commences ENDEAVOR Kyprolis Phase 3 trial for relapsed multiple myeloma

FDA ODAC votes in favor of Onyx’s Kyprolis

FDA ODAC votes in favor of Onyx’s Kyprolis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.